Skip to main content
main-content
Top

30-08-2022 | COVID-19 | News

Studies bolster evidence for COVID-19 vaccination in young people with RMDs

Author: Claire Barnard

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases (RMDs).

‘Excellent’ effectiveness of mRNA vaccine in adolescents

In the first study, Yosef Uziel (Meir Medical Center, Kfar Saba, Israel) and team used data from an Israeli insurance database to assess the ability of the Pfizer–BioNTech (BNT162b2) mRNA vaccine to prevent SARS-CoV-2 infection in 1639 adolescents aged 12–18 years with juvenile-onset RMDs.

This addresses an important knowledge gap, because most previous studies conducted in this population “have evaluated the immunogenicity (ability to induce humoral and cellular immune responses) of vaccines, rather than the effect of vaccination on infection rates (i.e. vaccine efficacy or effectiveness),” explain the researchers in Rheumatology.

In all, positive SARS-CoV-2 tests were reported in 16.9% of adolescents with RMDs who were vaccinated in February–December 2021 and in 51.9% of those who were not vaccinated. The median follow-up time after vaccination was 21.6 weeks, 19.0 weeks, and 8.9 weeks after the first, second, and third dose, respectively.

When the analysis was restricted to those who received at least two vaccine doses, COVID-19 occurred in 2.1% of 1009 adolescents with RMDs, and in 2.1% of 292,445 adolescents without RMDs who were vaccinated during the same period.

The researchers then calculated estimates for vaccine effectiveness, defined as one minus the risk ratio for vaccination relative to no vaccination. They say that this was “excellent,” and similar in the adolescents with versus without RMDs after one (76.3 vs 66.1%), two (94.8 vs 93.0%), and three (99.2 vs 99.5%) doses.

Uziel et al say that their study also “demonstrates that immunomodulatory drug treatment did not affect the effectiveness of the vaccine.”

Analysis of the cohort by diagnosis and drug treatment revealed that none of the patients with juvenile idiopathic arthritis (JIA) treated with an immunomodulatory agent – namely methotrexate (n=47), tumor necrosis factor inhibitors (n=84), or tocilizumab (n=7) – contracted COVID-19 after their second vaccine dose. Among the 91 adolescents with systemic lupus erythematosus (SLE), none of those who received two or three vaccine doses developed COVID-19 after completing their vaccinations.

“These results can encourage adolescents with [RMDs] to get vaccinated against COVID-19,” conclude the researchers.

Reassuring safety results in adolescents with a range of RMDs

The second study, from Kimme Hyrich (Manchester University NHS Foundation Trust, UK) and team, focused on the safety profile of COVID-19 vaccination in 36 adolescents (median age 15 years) with RMDs – including JIA (42%), SLE (14%), and spondyloarthropathies (14%) – who were included in the EULAR COVAX registry in 2021–2022.

The vast majority (92%) of patients were given the Pfizer–BioNTech vaccine; 44% had received the full recommended course of vaccinations, while the remaining 56% were partially vaccinated.

The team reports that disease flares postvaccination were “rare,” with one reactive arthritis patient experiencing a mild flare of polyarthralgia. Over half (56%) of patients experienced early adverse events (AEs) following vaccination, primarily fever (25%), injection site pain (22%), and generalized muscle pain (17%).

These AEs were “not unexpected as they are considered normal minor early side effects in the general population,” write the study authors in RMD Open.

“Overall, these data present a reassuring picture of rare disease flares and AEs after full or partial SARS-CoV- 2 vaccination,” they conclude.

Vaccination well tolerated in patients with Kawasaki disease

The final study used electronic medical records from 2020–2022 to describe the safety outcomes of 153 patients with Kawasaki disease (KD) aged an average of 13 years (range 5–21 years) who received at least one dose of an mRNA COVID-19 vaccine, primarily the Pfizer–BioNTech vaccine (93.5%).

Michael Portman and colleagues, from the Seattle Children’s Research Institute in Washington, USA, say that no clinically severe AEs, clinician or emergency department visits, or hospitalizations occurred within 30 days of vaccination in this cohort.

The team also evaluated outcomes of COVID-19 infection in a cohort of 37 individuals with KD (mean age 11 years), 10 of whom were vaccinated at the time of infection. None of the patients included in the study required hospital admission, and the most common symptoms – low-grade fever, fatigue, myalgia, and cough – resolved within a few days.

“Results of our study suggest that both COVID-19 and SARS-CoV-2 mRNA vaccination are well tolerated in patients with preceding KD,” concludes the team in JAMA Network Open.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

30 August 2022: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Rheumatology 2022; doi:10.1093/rheumatology/keac408
RMD Open 2022; 8: e002322
JAMA Netw Open 2022; 5: e2226236

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?